原始出處紀錄
決策級主要結果 (Topline)
Invivyd VYD2311 DECLARATION Phase 3 頂線數據預計2026年Q3
DECLARATION 關鍵試驗招募現已完成，頂線數據計劃於2026年Q3稍後公布，以支持潛在BLA提交。LIBERTY Phase 3試驗亦已完成給藥，頂線數據預計於2026年Q3末。
關鍵事實
- 申報時間
- 2026年8月13日 下午08:11
- 事件
- 主要結果 (Topline)
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand • DECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion • LIBERTY study fully dosed with top-line data anticipated in late Q3 2026 • Strong balance sheet with Q2 2026 ending cash and